Open AccessThe Efficacy and Tolerability of Nebivolol in Hypertensive African American Patients
Author(s) -
Saunders Elijah,
Smith William B.,
DeSalvo Karen B.,
Sullivan Will A.
Publication year - 2007
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2007.07548.x
Subject(s) - nebivolol , medicine , tolerability , placebo , blood pressure , adverse effect , beta blocker , diastole , cardiology , anesthesia , heart failure , alternative medicine , pathology
Hypertensive African Americans often respond poorly to β‐blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if β‐blockers with vasodilating effects are used. This 12‐week, multi‐center, double‐blind, randomized placebo‐controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating β 1 ‐blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] ≥95 mm Hg and ≤109 mm Hg). The primary efficacy end point was the baseline‐adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP ( P ≤.004) at all doses of 5 mg and higher and sitting systolic blood pressure ( P ≤.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well‐tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.